Archive for the ‘unreliable findings’ Category
Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest.
Also that year, suspicions about Chiba University hypertension researcher Issei Komuro’s work were first raised by an anonymous blog, which detailed numerous image manipulations in the researcher’s published works. Komuro, who frequently collaborated with Matsubara, has been a senior author on a number of valsartan papers, including the now-retracted one, which reported the results of Novartis-sponsored Valsartan Amlodipine Randomized Trial in 2011 without reporting the Novartis funding.
Back in May, we reported on a retraction from Molecular Cell that referred to a 2012 study the same group had published in Science. (A few weeks later, the lab head told us just how painful the process was.)
The journal Chemical Science has issued an expression of concern over a 2012 article by a pair of Texas researchers whose “unclick reaction” work has been under scrutiny by their institution.
The article, “Homonuclear bond activation using a stable N,N-diamidocarbene,” was written by Kelly M. Wiggins and Christopher W. Bielawski, of UT Austin. It’s the second EoC that we know of for a paper by Wiggins and Bielawski. We covered a previous one, from Science, that appeared in June.
Nature has issued an Expression of Concern for a paper co-authored by a scientist who threatened to sue us last year for writing about another Expression of Concern for one of his other papers.
Here’s the “Editorial Expression of Concern” for “Non-adaptive origins of interactome complexity:”
On Monday, we were first to report that a study of green coffee bean extract for weight loss touted on the Dr. Oz Show had been retracted.
Two authors of a 2012 paper sponsored by a company that made grand claims about green coffee bean extract’s abilities to help people lose weight have retracted it. The study was cited by The Dr. Oz Show, and last month it cost the company a $3.5 million settlement with the Feds.
Here’s the notice for “Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects,” a paper originally published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy: Read the rest of this entry »
We’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.
Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.
The paper, “The Effect of Soluble RAGE on Inhibition of Angiotensin II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice,” came from a group of researchers in South Korea.
It purported to show that: Read the rest of this entry »
Another stem cell paper has been retracted from Nature, this one a highly cited 2008 study that had already been the subject of what the journal’s news section called a “furore” in 2010.
According to that 2010 news story:
The researchers behind the original work1, led by Thomas Skutella of the University of Tübingen, reported using cells from adult human testes to create pluripotent stem cells with similar properties to embryonic stem cells.
But a 2010 Brief Communication Arising called those findings into question. And now, the authors have retracted the paper. Here’s the notice for “Generation of pluripotent stem cells from adult human testis:” Read the rest of this entry »